Phosphagen. Share Discussion Threads

[donaferentes] 16/5/2008 18:45

Last fund-raising was not available to AIM/UK investors. This company almost always ignores its London presence and is the one reason why my faith in it may not last. Their NOMAD needs to pull their finger out and advise them that UK investors are due equal consideration to the Ozzies home team.

[ladybird1] 16/5/2008 13:51

Brave man, outsize, considering buying a few more!

Selling a further 10% of the equity, at this price & for a pretty small amount, doesn't give a lot of confidence that there will be positive news in this calender year or early 2009. The Nestle deal going bad, for instance?

Whatever, the contrast is stark between this rather shifty bit of fund raising from institutions & 'sophisticated investors' & the last fund raising which they felt able to make available to all holders (not easy in the UK admittedly, but the general principle of confidence was clear).

They've been very quiet this time round. Why? - they're not usually shy at blowing the trumpet. The next update on progress will be of interest.

[outsizeclothes.com] 16/5/2008 12:12

Tried to buy this morning at 7.5p here, ( way above the Oz closing @ 14c [[6.8p]] but it wouldn't fill. MM's being stupidly greedy, as they could do an arbitrage buying in Oz and selling to me.
I only wish my broker could buy in Oz.

[ladybird1] 16/5/2008 09:44

Rattling down again on largish volume for the stock. This fund raising really does make you wonder.

[ladybird1] 15/5/2008 08:32

Further decline in Oz to 14/15, with large volume. Largish holdong being sold out?

Raising what is only a few months funding at this level does not inspire confidence that they foresee having a good story to tell in the near/medium term.

[outsizeclothes.com] 14/5/2008 23:10

Bid/Offer in Oz is 15/15.5c, below the UK bid 7.5p

At 7.44p equivalent, buying in Oz looks a lot more sensible that paying 8.5p here.

[ladybird1] 10/5/2008 22:43

A depressing comparison with the last fundraising, despite the apparently favourable progress.

[hopeless698] 08/5/2008 16:33

spaceparallax...think it's GBP 4,393,827 to be exact!

[spaceparallax] 08/5/2008 12:35

Anyone able to provide a Sterling equivalent for the issue price?

[gavapentin] 07/5/2008 08:56

now we know why it has been poor for the past few months
the players knew about this
might start to see steady rise after 15 May imo

[hopeless698] 07/5/2008 07:48

07 May 2008
Company Announcement
Phosphagenics Completes A$9.1 M Capital Raising
Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has raised A$9.1 m via a placement of approximately 60.6 million fully paid ordinary shares to leading overseas and domestic institutions, and other sophisticated investors, at 15 cents per share.
It is expected that trading in the new shares on the Australian Stock Exchange will commence on or around 12 May 2008.

Mr Harry Rosen, Phosphagenics' President & CEO said that the company was very pleased with the response from investors.
"We are very pleased to receive this substantial support from our existing shareholders as we continue to focus on the discovery of new and cost-effective ways to enhance the bioavailability, delivery, efficacy and safety of proven pharmaceutical and nutraceutical products," Mr Rosen said.
"The funds raised considerably strengthen the Company's financial position and together with government grants and other revenue will support Phosphagenics' research and development programs through to the end of calendar year 2009," he said.

Attached for release to the market is an Appendix 3B notice together with a Section 708A
notice.
ENDS.......
APPENDIX AND NOTES TO EDITORS
About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around the science and application of
phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, efficacy and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.

[donaferentes] 06/5/2008 07:39

As ever they've forgotten about their listing on AIM. No suspension announced here today.

[ladybird1] 05/5/2008 09:45

I can't copy the PDF file containing the announcement, but it can be viewed at the company website or on ASX.

The company has suspended trading on its shares until Wednesday or later, 'pending the release of an announcement'. It refers to a capital raising.

[ladybird1] 02/5/2008 10:14

Continuing to drift gently south in Australia, on low volumes. I hope the Nestle agreement will emerge in the not too distant future & refocus attention.

On the plus side, the decline in sterling against the A$ steadies the price in the UK & any move upside for the share will of course also benefit from it.

[donaferentes] 30/4/2008 07:35

another seemingly faultless step along the way - another year or two of patience required though,

[hopeless698] 30/4/2008 07:24

Pre-Clinical Trial Results




RNS Number:4072T
Phosphagenics Limited
30 April 2008


30 April 2008


Company Announcement



Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of
Lidocaine


- Company's TPM Drug Delivery Technology Demonstrates Substantial Increase in
Lidocaine Penetration Compared to a Leading Marketed Product -



Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today
announced positive results of a pre-clinical study using TPM, the Company's
patented drug deliver system, for the targeted delivery of lidocaine,
demonstrating increased efficacy while restricting systemic exposure. A phase 1
human clinical trial is scheduled to commence in the third quarter of 2008.



Study Design



The study was designed to demonstrate the ability of TPM to deliver lidocaine
(5%) to a targeted local site after a single topical application, while
restricting systemic exposure. Lidocaine concentrations were measured in the
skin at the site of application as well as in the underlying muscle and tissue.
The studies were performed in parallel using a leading commercial form of
lidocaine, Xylocaine(R) 5%, to assess the relative efficacy of the TPM/Lidocaine
formulation.



TPM/Lidocaine or Xylocaine(R) (20microgram) were applied to a 2x2 cm2 area of
shaved skin on the thigh of the treatment, or control animals (n=10). Blood
samples were taken at 0 (before application), 1, 2, 3, and 5 hours after
application. Lidocaine concentrations were measured in the skin at the site of
application as well as in the underlying muscle to determine the amount of
lidocaine delivered to the local area of application. Plasma lidocaine
concentration was quantified to evaluate systemic exposure.



Study Results



Phosphagenics' TPM/Lidocaine increased, by a statistically significant margin
(p London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1
program was established in the U.S. with The Bank of New York Mellon (PPGNY) for
U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter'
market. In July 2007, this was upgraded to the International OTCQX, a new
premium market tier in the U.S. for international exchange-listed companies,
operated by Pink Sheets, LLC.



For more information, please visit Phosphagenics' web site at
www.phosphagenics.com



Safe Harbor Statement

This press release contains forward-looking statements based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialise, actual results could vary materially
from the Phosphagenics' expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic conditions, such
as interest rate and currency exchange rate fluctuations; technological advances
and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; domestic and foreign
health care reforms and governmental laws and regulations.



Company Contact Details: U.S. Investor and Media Contacts:
Esra Ogru Brian Ritchie
Phosphagenics Limited Financial Dynamics
Executive VP R&D [phone]
[phone]


Mary McSwiggan
Phosphagenics Limited
Investor Relations Manager
[phone]

[rambutan2] 22/4/2008 22:38

Yes, the ASX listing makes it ISAable - I've got it in mine.

[donaferentes] 22/4/2008 09:01

Here's the link- sorry copy and paste - forgotten how to make it a true link.


Excellence_in_Biotechnology_Investment_Conference_Presentation.pdf

still making steady progress without discernible fault. patience required

PS: can anyone confirm PSG is ISAable, although AIM it is listed on Aus market and dealt with in US?? TIA

[lgw] 21/4/2008 17:47

encouraging presentation, shows that we are not that far from commerciality on many fronts and also cash at dec 07 AUS $10.7mill.
Add to that cash the grants money receivable 08 and also any other investment we may pick up from the conference.

[rambutan2] 14/4/2008 14:03

Would be nice to think that one of PSG's ventures will give us a boost during this year.

On the downside, I suppose the cash sit could become an issue. Could do with a nice payment from someone, or the share price shooting up to a level which doesn't dilute us.

[cestnous] 27/3/2008 13:20

Not in yet, but this is very encouraging. Below from USA GOV. info on frequently asked questions about GRAS




If I submit a GRAS notice, how long will it take for me to receive a response from FDA?

Our goal is to respond to most GRAS notices within 180 days.

If I submit a GRAS notice about a food substance, must I wait until I receive a response from FDA before I market that substance?

No. If one is correct in determining that the intended use of an ingredient is GRAS, use of the ingredient is not subject to any legal requirement for FDA review and approval. Your decision to submit a GRAS notice is voluntary, and FDA's response to a GRAS notice is not an approval. You may market a substance that you determine to be GRAS for a particular use without informing FDA or, if FDA is so informed, while FDA is reviewing that information (62 Fed. Reg. 18951; April 17, 1997). We recognize, however, that some firms prefer to know that FDA has reviewed its notice of a GRAS determination, without raising safety or legal issues, before marketing.

[spaceparallax] 19/3/2008 10:27

More positive news - very welcome in our current Market climate.

[lgw] 18/3/2008 12:59

The Nestle Funded phase 2 Clinical trial is underway in 3 locations and due to be concluded before June and now we have Gras status for Phospha E -We could actually see Butter/spreads, Breakfast cereals etc all containing Phospha E on our Supermarket shelves within a few months-
In the words of Harry Rosen
"GRAS status extends the permitted use of Phospha E(R) beyond the nutritional
supplement market and into the substantial U.S. food industry, and represents a
tremendous commercial opportunity for Phosphagenics," said Harry Rosen,
Phosphagenics' President and CEO."

An interesting few months ahead, I will hold my PSG shares tightly.